Gastric cancer is the 5th most common cancer and the
5th leading cause of cancer-related death
worldwide2
of patients with gastric cancer have advanced disease* at the time of diagnosis3
**Defined in any percentage of tumor cell with moderate (2+) to strong (3+) membranous staining.11
††In ~ 16% of all cases, overexpression is observed in ≥ 10% of tumor cells.
Reflexively testing for actionable IHC biomarkers at gastric/GEJ cancer diagnosis can help guide timely, personalized treatment decisions14
*This includes patients with regional disease, or those whose cancer has spread to regional lymph nodes, and metastatic disease at the time of diagnosis. There will be an estimated 30,300 new cases in the United States in 2025.3
†Based on a retrospective observational cohort study of 2,029 patients aged ≥ 65 years with metastatic gastric/GEJ cancer who initiated 1L systemic anticancer therapy between April 16, 2021 and February 29, 2024. Data was extracted from the 100% Medicare Fee-for-Service database.6
‡Assessed between 2015 and 2021 in the United States.3
§ Defined as ≥ 75% of tumor cells with moderate (2+) to strong (3+) membranous staining.10
‡‡Testing recommendations for GEJ cancers, HER2, and CLDN18.2 are in adenocarcinoma. The NCCN Guidelines recommend testing for PD-L1 and MMR by IHC in all newly diagnosed patients.12,13
1L, first line; CLDN18.2, claudin-18 isoform 2; CPS, combined positive score; dMMR, deficient mismatch repair; FGFR2b, fibroblast growth factor receptor 2, isoform IIIb; FISH, fluorescence in situ hybridization; GEJ, gastroesophageal junction; HER2, human epidermal growth factor receptor 2; MMR, mismatch repair; MSI-H, microsatellite instability-high; NCCN, National Comprehensive Cancer Network; NGS, next-generation sequencing; OS, overall survival; PD-L1, programmed cell death ligand 1.
References: 1. Sato Y, et al. J Clin Med. 2023;12:4646. 2. Bray F, et al. CA Cancer J Clin. 2024;74:229-263. 3. National Cancer Institute. https://seer.cancer.gov/statfacts/html/stomach.html. Accessed April 25, 2025. 4. Janjigian YY et al. J Clin Oncol. 2024;42:2012-2020. 5. Shah MA, et al. Nat Med. 2023;29:2133-2141. 6. Chen Z, et al. Presented at: International Society for Pharmacoeconomics and Outcomes Research; May 13–16, 2025; Montreal, QC, Canada. Abstract EE423. 7. Van Cutsem E, et al. Gastric Cancer. 2015;18:476-484. 8. Amonkar M, et al. J Clin Oncol. 2019;37:e15074. 9. Schoemig-Markiefka B, et al. Gastric Cancer. 2021;24:1115-1122. 10. Shitara K, et al. Lancet. 2023;401:1655-1668. 11. Rha SY, et al. JCO Precis Oncol. 2025;9:e2400710. 12. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Gastric Cancer V.3.2025. ©National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed August 22, 2025. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way. 13. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Esophageal and Esophagogastric Junction Cancers V.4.2025. ©National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed August 22, 2025. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way. 14. Anand K, et al. Clin Lung Cancer. 2020;21:437-442.
References: 1. FPO 2. FPO 3. FPO